Your browser doesn't support javascript.
loading
Germline variants associated with toxicity to immune checkpoint blockade.
Groha, Stefan; Alaiwi, Sarah Abou; Xu, Wenxin; Naranbhai, Vivek; Nassar, Amin H; Bakouny, Ziad; El Zarif, Talal; Saliby, Renee Maria; Wan, Guihong; Rajeh, Ahmad; Adib, Elio; Nuzzo, Pier V; Schmidt, Andrew L; Labaki, Chris; Ricciuti, Biagio; Alessi, Joao Victor; Braun, David A; Shukla, Sachet A; Keenan, Tanya E; Van Allen, Eliezer; Awad, Mark M; Manos, Michael; Rahma, Osama; Zubiri, Leyre; Villani, Alexandra-Chloe; Fairfax, Benjamin; Hammer, Christian; Khan, Zia; Reynolds, Kerry; Semenov, Yevgeniy; Schrag, Deborah; Kehl, Kenneth L; Freedman, Matthew L; Choueiri, Toni K; Gusev, Alexander.
Afiliación
  • Groha S; Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Alaiwi SA; Broad Institute of Harvard & MIT, Cambridge, MA, USA.
  • Xu W; Harvard Medical School, Boston, MA, USA.
  • Naranbhai V; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Nassar AH; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • El Zarif T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Saliby RM; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Wan G; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Rajeh A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Adib E; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Nuzzo PV; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Schmidt AL; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Ricciuti B; Harvard Medical School, Boston, MA, USA.
  • Alessi JV; Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
  • Braun DA; Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
  • Shukla SA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Keenan TE; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Van Allen E; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Awad MM; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy.
  • Manos M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Rahma O; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Zubiri L; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Villani AC; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy.
  • Fairfax B; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hammer C; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Khan Z; Broad Institute of Harvard & MIT, Cambridge, MA, USA.
  • Reynolds K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Semenov Y; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Schrag D; Broad Institute of Harvard & MIT, Cambridge, MA, USA.
  • Kehl KL; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Freedman ML; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
  • Choueiri TK; Broad Institute of Harvard & MIT, Cambridge, MA, USA.
  • Gusev A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nat Med ; 28(12): 2584-2591, 2022 12.
Article en En | MEDLINE | ID: mdl-36526723
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Estudio de Asociación del Genoma Completo / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Estudio de Asociación del Genoma Completo / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2022 Tipo del documento: Article